PepGen (PEPG) Projected to Post Earnings on Thursday

PepGen (NASDAQ:PEPG) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect PepGen to post earnings of ($0.71) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.15. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Price Performance

PepGen stock opened at $4.53 on Tuesday. The firm has a market capitalization of $148.58 million, a PE ratio of -1.53 and a beta of 1.95. The company’s 50-day moving average is $3.40 and its 200-day moving average is $2.09. PepGen has a fifty-two week low of $0.88 and a fifty-two week high of $7.50.

Insider Transactions at PepGen

In other PepGen news, major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of the business’s stock in a transaction on Tuesday, September 30th. The stock was purchased at an average price of $3.20 per share, with a total value of $640,000.00. Following the acquisition, the insider directly owned 4,955,388 shares of the company’s stock, valued at approximately $15,857,241.60. This trade represents a 4.21% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of PepGen

A number of institutional investors have recently bought and sold shares of the business. Woodline Partners LP bought a new stake in PepGen in the 1st quarter valued at about $1,097,000. Bridgeway Capital Management LLC lifted its holdings in shares of PepGen by 61.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock worth $102,000 after acquiring an additional 35,000 shares during the period. AQR Capital Management LLC bought a new stake in shares of PepGen during the 1st quarter worth approximately $122,000. Qube Research & Technologies Ltd bought a new stake in shares of PepGen during the 2nd quarter worth approximately $81,000. Finally, Marshall Wace LLP bought a new stake in shares of PepGen during the 2nd quarter worth approximately $44,000. Institutional investors own 58.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of PepGen from $12.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Stifel Nicolaus lifted their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Guggenheim reaffirmed a “buy” rating and set a $6.00 target price on shares of PepGen in a report on Wednesday, September 24th. Wedbush lifted their target price on shares of PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, PepGen presently has an average rating of “Hold” and an average price target of $9.60.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.